

Nancy Berliner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1198271/publications.pdf>

Version: 2024-02-01

157
papers

4,652
citations

109137

35
h-index

102304

66
g-index

160
all docs

160
docs citations

160
times ranked

6333
citing authors

#	ARTICLE	IF	CITATIONS
1	Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2023, 7, 2309-2316.	2.5	6
2	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2022, 139, 1098-1110.	0.6	46
3	Introduction to a review series on COVID-19 and the hematologist. <i>Blood</i> , 2022, 140, 163-164.	0.6	1
4	The utility of the novel optimized HLH inflammatory (OHI) index for predicting the risk for mortality and causes of death in lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 7570-7570.	0.8	0
5	Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522199588.	0.5	2
6	A novel index using inflammatory markers improves the diagnosis of hemophagocytic lymphohistiocytosis in patients with hematologic malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 7563-7563.	0.8	1
7	To "Lump" or to "Split" in Macrophage Activation Syndrome and Hemophagocytic Lymphohistiocytosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 206-209.	2.9	8
8	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2020, 136, 3051-3055.	0.6	15
9	Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 697-704.	0.9	18
10	Effects of Interleukin-1 ² Inhibition on Incident Anemia. <i>Annals of Internal Medicine</i> , 2020, 172, 523.	2.0	37
11	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	2.0	126
12	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.	1.7	7
13	Introduction to a How I Treat series on hematologic complications in pregnancy. <i>Blood</i> , 2020, 136, 2093-2093.	0.6	0
14	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.	1.6	5
15	Changing of the guard the old and the new. <i>Blood</i> , 2020, 135, 1-1.	0.6	1
16	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 925-929.	2.5	8
17	A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
18	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	0.6	21

#	ARTICLE	IF	CITATIONS
19	Targeting the inflammatory cascade in haemophagocytic lymphohistiocytosis. <i>Lancet Haematology</i> , 2019, 6, e602-e603.	2.2	2
20	Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2019, 134, 1783-1786.	0.6	108
21	Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. <i>Blood</i> , 2019, 133, 2465-2477.	0.6	587
22	Introduction to a review series on human neutrophils. <i>Blood</i> , 2019, 133, 2111-2112.	0.6	5
23	Fostamatinib for the treatment of chronic immune thrombocytopenia. <i>Blood</i> , 2019, 133, 2027-2030.	0.6	64
24	CD4+ Tâ€œcell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year. <i>Transfusion</i> , 2019, 59, 1644-1647.	0.8	7
25	Targeting the mTOR pathway in idiopathic multicentric Castleman disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 4086-4088.	3.9	4
26	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 2719-2719.	0.6	0
27	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 5166-5166.	0.6	0
28	Hemophagocytic Lymphohistiocytosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 27-49.	9.6	299
29	The rheumatology/hematology interface: CAPS and MAS diagnosis and management. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 313-317.	0.9	9
30	CD4+ T-Cell Lymphopenia in Frequent Platelet Donors Who Have Ceased Platelet Donation for at Least 1 Year. <i>Blood</i> , 2018, 132, 2550-2550.	0.6	0
31	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. <i>Blood</i> , 2018, 132, 1533-1533.	0.6	0
32	Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs. <i>Blood</i> , 2018, 132, 2235-2235.	0.6	0
33	Metformin treatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. <i>Blood</i> , 2018, 132, 1532-1532.	0.6	0
34	Introduction to a series of reviews on clinical platelet disorders. <i>Blood</i> , 2017, 129, 2821-2822.	0.6	2
35	Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience. <i>British Journal of Haematology</i> , 2017, 177, 979-983.	1.2	9
36	Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 889-897.	0.5	6

#	ARTICLE	IF	CITATIONS
37	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1807-1814.	2.5	8
38	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.	2.5	0
39	Nancy Berliner Reflects on a Career Unscripted. , 2017, 14, .		0
40	Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7Âyears. <i>British Journal of Haematology</i> , 2016, 172, 412-419.	1.2	119
41	Which â€™roid is all the rage?. <i>Blood</i> , 2016, 127, 273-273.	0.6	0
42	Sickle cell disease: challenges and progress. <i>Blood</i> , 2016, 127, 789-789.	0.6	18
43	Management of Dabigatranâ€™Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis. <i>Pharmacotherapy</i> , 2016, 36, e160-e165.	1.2	35
44	Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 616-622.	1.0	17
45	Case 1-2016. <i>New England Journal of Medicine</i> , 2016, 374, 165-173.	13.9	9
46	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5815-5815.	0.6	0
47	The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 183-189.	0.9	40
48	Marked hyperferritinemia does not predict for HLH in the adult population. <i>Blood</i> , 2015, 125, 1548-1552.	0.6	170
49	How I treat hemophagocytic lymphohistiocytosis in the adult patient. <i>Blood</i> , 2015, 125, 2908-2914.	0.6	293
50	High $\hat{N}p73/TAp73$ ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.	0.6	28
51	The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 37.	6.9	10
52	Implementation of a Hemostatic and Antithrombotic Stewardship program. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 379-382.	1.0	35
53	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	1.4	128
54	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	0.8	31

#	ARTICLE	IF	CITATIONS
55	Hemophagocytic Lymphohistiocytosis in Adults. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 915-925.	0.9	64
56	Congenital and Acquired Disorders of Macrophages and Histiocytes. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, xiii-xv.	0.9	1
57	Hemophagocytic Syndrome and Critical Illness. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 401-412.	1.3	80
58	Lâ€œLeucine improves the anaemia in models of Diamond Blackfan anaemia and the 5qâ€œ syndrome in a <sc>TP</sc>53â€œ independent way. <i>British Journal of Haematology</i> , 2014, 167, 524-528.	1.2	27
59	Prognostic impact of <i><sc>KMT</sc>2E</i> transcript levels on outcome of patients with acute promyelocytic leukaemia treated with allâ€œtrans retinoic acid and anthracyclineâ€œbased chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , 2014, 166, 540-549.	1.2	13
60	Differentiation and Characterization of Myeloid Cells. <i>Current Protocols in Immunology</i> , 2014, 104, 22F.5.1-22F.5.28.	3.6	84
61	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	0.8	58
62	How we evaluate and treat neutropenia in adults. <i>Blood</i> , 2014, 124, 1251-1258.	0.6	93
63	Hemophagocytic Lymphohistiocytosis: The Partners Healthcare Experience over the Past 8 Years. <i>Blood</i> , 2014, 124, 4104-4104.	0.6	2
64	â€œAsk and Ye Shall Receiveâ€œâ€œ Women, Stand Up and Be Counted!. , 2014, 11, .		0
65	Haploinsufficiency of NPM1 in AML Derived NPM1 Mutant (NPMc+) Expressing Cells Contributes to Aberrant C/EBPÎ± Activity. <i>Blood</i> , 2014, 124, 2188-2188.	0.6	0
66	Marked Hyperferritinemia Does Not Predict for Hemophagocytic Lymphohistiocytosis (HLH) in the Adult Population. <i>Blood</i> , 2014, 124, 4951-4951.	0.6	0
67	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.	0.6	96
68	Mutant Nucleophosmin 1(NPMc+) Mislocalizes The p40 Isoform Of The Master Myeloid Transcriptional Regulator C/EBPÎ± To The Cytoplasm: Implications In AML. <i>Blood</i> , 2013, 122, 1417-1417.	0.6	0
69	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , 2013, 122, 2586-2586.	0.6	0
70	Anemia in the elderly. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 230-7.	0.9	28
71	Up-regulation of Translation Eukaryotic Initiation Factor 4E in Nucleophosmin 1 Haploinsufficient Cells Results in Changes in CCAAT Enhancer-binding Protein Î± Activity. <i>Journal of Biological Chemistry</i> , 2012, 287, 32728-32737.	1.6	17
72	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , 2012, 120, 1407-1407.	0.6	0

#	ARTICLE	IF	CITATIONS
73	L-Leucine Improves the Anemia of DBA and the 5q- Syndrome Via Activation of the mTOR Pathway in a p53-Independent Manner. <i>Blood</i> , 2012, 120, 1257-1257.	0.6	0
74	Design and Validation of a High-Throughput Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Method for Quantification of Hepcidin in Human Plasma. <i>Analytical Chemistry</i> , 2011, 83, 8357-8362.	3.2	20
75	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, xiii.	0.9	3
76	Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. <i>Blood</i> , 2011, 117, 2800-2806.	0.6	99
77	Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. <i>Blood</i> , 2011, 117, 2567-2576.	0.6	347
78	Resveratrol ameliorates TNF α -mediated suppression of erythropoiesis in human CD34 ⁺ cells via modulation of NF κ B signalling. <i>British Journal of Haematology</i> , 2011, 155, 93-101.	1.2	15
79	Dabigatran. <i>Critical Pathways in Cardiology</i> , 2011, 10, 117-127.	0.2	11
80	Heparin-Induced Thrombocytopenia and Cardiac Surgery: A Role for Hematologists in Critical Care Units. <i>Blood</i> , 2011, 118, 2062-2062.	0.6	4
81	Upregulation of eIF4E in Nucleophosmin 1 (NPM1) Haploinsufficient Cells Alters CCAAT Enhancer Binding Protein Alpha (C/EBP α) Activity: Implications for MDS and AML. <i>Blood</i> , 2011, 118, 2432-2432.	0.6	0
82	Clinical Significance of Coagulation Studies in Predicting Response to Recombinant Factor VIIa in Cardiac Surgery Patients. <i>Blood</i> , 2011, 118, 4351-4351.	0.6	0
83	1, 25-Dihydroxyvitamin D Suppresses TNF α -Mediated NF κ B Activation in K562 and Human CD34 ⁺ Cells and Promotes Recovery of Erythroid Colony Formation in Human CD34 ⁺ Cells. <i>Blood</i> , 2011, 118, 2097-2097.	0.6	0
84	L-Leucine Improves the Anemia of the 5q- Syndrome Via Activation of the mTOR (mammalian target of) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	0
85	correspondence: Single nucleotide polymorphisms in the human <i>TNF</i> gene are associated with anaemia and neutropenia in a cohort of patients with <i>de novo</i> myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2010, 150, 700-701.	1.2	15
86	Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 942-949.	3.0	55
87	Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 415-420.	12.5	72
88	Treatment of Zebrafish Models of Ribosomopathies (Diamond Blackfan Anemia (DBA) and 5q- Syndrome) with L-Leucine Results In An Improvement of Anemia and Developmental Defects: Evidence for a Common Pathway?. <i>Blood</i> , 2010, 116, 195-195.	0.6	1
89	Role for MKL1 in megakaryocytic maturation. <i>Blood</i> , 2009, 113, 2826-2834.	0.6	67
90	ASH $\text{\textcircled{R}}$'s Voice in the Health Reform Debate. , 2009, 6, .		0

#	ARTICLE	IF	CITATIONS
91	Moving Beyond the "in ASH. , 2009, 6, .		0
92	Let the Good Times Roll in New Orleans. , 2009, 6, .		0
93	Looking Ahead to New Orleans: Issues and Opportunities. , 2009, 6, .		0
94	The Ongoing COI Debate. , 2009, 6, .		0
95	Nucleophosmin-1 Interacts with CCAAT Enhancer Binding Protein Alpha (C/EBP β) to Facilitate Granulocyte Maturation: Implications in MDS and AML.. Blood, 2009, 114, 2768-2768.	0.6	0
96	Resveratrol Ameliorates TNF α -Mediated Suppression of Erythroid Colony Formation in Human CD34+ Cells Via Cellular Pathways Involving Downregulation of NF- κ B.. Blood, 2009, 114, 2507-2507.	0.6	0
97	Nucleophosmin Is Required for Macrophage Function and Maturation.. Blood, 2009, 114, 238-238.	0.6	1
98	A cascade of Ca ²⁺ /calmodulin-dependent protein kinases regulates the differentiation and functional activation of murine neutrophils. Experimental Hematology, 2008, 36, 832-844.	0.2	13
99	Mouse neutrophils lacking lamin B-receptor expression exhibit aberrant development and lack critical functional responses. Experimental Hematology, 2008, 36, 965-976.	0.2	44
100	Lessons from congenital neutropenia: 50 years of progress in understanding myelopoiesis. Blood, 2008, 111, 5427-5432.	0.6	41
101	Generation of a Factor Dependent Myeloid Cell Line from Nucleophosmin-1 Heterozygous (NPM-1+/ \hat{a}) Mouse Bone Marrow as a Model for 5q- MDS. Blood, 2008, 112, 852-852.	0.6	0
102	Post-Translational Modification and Differential Protein Binding Partners of CCAAT Enhancer Binding Protein Alpha (C/EBP β) p42 Versus p30 May Contribute to Aberrant C/EBP β Activity in Acute Leukemia. Blood, 2008, 112, 3577-3577.	0.6	0
103	Growth factor independence-1 (Gfi-1) plays a role in mediating specific granule deficiency (SGD) in a patient lacking a gene-inactivating mutation in the C/EBP μ gene. Blood, 2007, 109, 4181-4190.	0.6	56
104	ATRA: Finding targeted APL therapy targets. Blood, 2007, 110, 476-477.	0.6	1
105	Differential Transactivation Activities of Sumoylated CCAAT Enhancer Binding Protein alpha (C/EBP β) p42 Versus p30 May Contribute in Part, to Aberrant C/EBP β Activity in Acute Leukemias.. Blood, 2007, 110, 1231-1231.	0.6	0
106	Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nature Clinical Practice Oncology, 2006, 3, 165-168.	4.3	14
107	Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1. Neuro-Oncology, 2006, 8, 280-283.	0.6	62
108	Effect of Factor V Leiden and Prothrombin G20210 \hat{a} A Mutations on Thromboembolic Risk in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. Journal of the National Cancer Institute, 2006, 98, 904-910.	3.0	55

#	ARTICLE	IF	CITATIONS
109	Human neutrophil collagenase expression is C/EBP-dependent during myeloid development. <i>Experimental Hematology</i> , 2005, 33, 42-52.	0.2	23
110	Early Transcriptional Response of Human Neutrophils to <i>Anaplasma phagocytophilum</i> Infection. <i>Infection and Immunity</i> , 2005, 73, 8089-8099.	1.0	44
111	<i>Anaplasma phagocytophilum</i> Modulates gp91phox Gene Expression through Altered Interferon Regulatory Factor 1 and PU.1 Levels and Binding of CCAAT Displacement Protein. <i>Infection and Immunity</i> , 2005, 73, 208-218.	1.0	36
112	Heterogeneity of functional responses in differentiated myeloid cell lines reveals EPRO cells as a valid model of murine neutrophil functional activation. <i>Journal of Leukocyte Biology</i> , 2005, 77, 669-679.	1.5	29
113	Modulation of NB4 promyelocytic leukemic cell machinery by <i>Anaplasma phagocytophilum</i> . <i>Genomics</i> , 2005, 86, 365-377.	1.3	42
114	Tâ€Cell Large Granular Lymphocyte Leukemia and Related Disorders. <i>Oncologist</i> , 2004, 9, 247-258.	1.9	134
115	G-CSF signaling can differentiate promyelocytes expressing a defective retinoic acid receptor: evidence for divergent pathways regulating neutrophil differentiation. <i>Blood</i> , 2004, 103, 1693-1701.	0.6	25
116	Chromatin immunoprecipitation (ChIP) studies indicate a role for CCAAT enhancer binding proteins alpha and epsilon (C/EBPÎ± and C/EBPÎµ) and CDP/cut in myeloid maturation-induced lactoferrin gene expression. <i>Blood</i> , 2003, 101, 3460-3468.	0.6	52
117	Development of a murine hematopoietic progenitor complementary DNA microarray using a subtracted complementary DNA library. <i>Blood</i> , 2002, 100, 833-844.	0.6	25
118	Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line. <i>Blood</i> , 2002, 100, 3209-3220.	0.6	88
119	Genomic and proteomic analysis of the myeloid differentiation program. <i>Blood</i> , 2001, 98, 513-524.	0.6	94
120	Molecular biology of neutrophil differentiation. <i>Current Opinion in Hematology</i> , 1998, 5, 49-53.	1.2	32
121	Lymphoproliferative disorder of granular lymphocytes associated with severe neutropenia. Response to granulocyte colony-stimulating factor. <i>Cancer</i> , 1993, 72, 1607-1611.	2.0	14
122	Genomic structure and mapping of the chromosomal gene for transcobalamin I (TCN1): Comparison to human intrinsic factor. <i>Genomics</i> , 1992, 12, 459-464.	1.3	48
123	Systemic lupus erythematosus is not genetically linked to the beta chain of the T cell receptor. <i>Arthritis and Rheumatism</i> , 1986, 29, 1023-1025.	6.7	19
124	Uptake and metabolism of free cyanocobalamin by cultured human fibroblasts from controls and a patient with transcobalamin II deficiency. <i>Metabolism: Clinical and Experimental</i> , 1981, 30, 230-236.	1.5	36
125	Anemias, Red Cells, and the Essential Elements of Red Cell Homeostasis. , 0, , 1-13.		1
126	Red Cell Production. , 0, , 14-18.		0

#	ARTICLE	IF	CITATIONS
127	Red Blood Cell Life Span, Senescence, and Destruction. , 0, , 19-22.		1
128	The Clinical Approach to the Patient with Anemia. , 0, , 23-33.		0
129	Anemia in Children. , 0, , 34-38.		0
130	Iron Deficiency Anemia. , 0, , 39-43.		1
131	Sideroblastic Anemias. , 0, , 44-47.		0
132	The Thalassemia Syndromes. , 0, , 48-58.		1
133	Macrocytic Anemias. , 0, , 59-65.		0
134	Sickle Cell Syndromes. , 0, , 66-75.		0
135	Structural Hemoglobinopathies. , 0, , 76-83.		1
136	Autoimmune Hemolytic Anemia. , 0, , 84-94.		0
137	Drug-Induced Hemolytic Anemia. , 0, , 95-99.		0
138	Red Cell Membrane Defects. , 0, , 100-107.		0
139	Microangiopathic Hemolytic Anemia. , 0, , 113-121.		0
140	Extrinsic Nonimmune Hemolytic Anemias. , 0, , 122-127.		0
141	Acquired Aplastic Anemia and Pure Red Cell Aplasia. , 0, , 128-136.		0
142	Paroxysmal Nocturnal Hemoglobinuria. , 0, , 137-142.		0
143	Congenital Marrow Failure Syndromes. , 0, , 143-149.		0
144	Anemia of Chronic Inflammation. , 0, , 150-155.		0

#	ARTICLE	IF	CITATIONS
145	Myelodysplasia. , 0 , 156-166.		0
146	HIV and Anemia. , 0 , 167-171.		0
147	Anemia in the Patient with Cancer. , 0 , 172-178.		1
148	Secondary Anemias Associated with Hematopoietic Stem Cell Transplantation. , 0 , 179-184.		0
149	The Anemia of Aging. , 0 , 185-189.		0
150	Anemia in Pregnancy. , 0 , 190-193.		0
151	Anemias Due to Systemic Diseases. , 0 , 194-200.		0
152	Transfusion Therapy for Anemia. , 0 , 201-206.		0
153	Transfusion Reactions. , 0 , 207-216.		0
154	Pharmacologic Therapy of Anemia. , 0 , 217-222.		0
155	Splenectomy. , 0 , 223-228.		0
156	Anemias. , 0 , 229-233.		0
157	Putting the Heme Back in Heme-Onc: an Evaluation of the Redesigned Hematology Track within the Dana Farber/Mass General Brigham Hematology-Oncology Fellowship. Journal of Cancer Education, 0 , .	0.6	1